Adimab, Biogen Idec, GlaxoSmithKline deal
In separate deals, Adimab granted non-exclusive licenses to Biogen Idec and GlaxoSmithKline to internalize Adimab's yeast-based antibody discovery platform to discover and optimize antibody-based therapeutics, including bispecific antibodies. Each partner will use the platform to identify antibodies in undisclosed therapeutic areas. Adimab said it is the first time it has allowed partners to internalize the platform.
Biogen Idec and GSK will receive a unique custom human antibody library that is exclusive to each company and an option to receive platform improvements, including access to new antibody libraries. Under both deals, Adimab will receive an upfront payment and is eligible for undisclosed milestones, plus royalties. The pharma also will pay Adimab annual license fees. Adimab and GSK declined to provide details, and Biogen Idec could not be reached. ...